- Home
- DGNX vs CDNA Comparison
DGNX vs CDNA Comparison
Compare DGNX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- CDNA
- Stock Information
- Founded
- DGNX 2018
- CDNA 1998
- Country
- DGNX United Kingdom
- CDNA United States
- Employees
- DGNX N/A
- CDNA N/A
- Industry
- DGNX
- CDNA Medical Specialities
- Sector
- DGNX
- CDNA Health Care
- Exchange
- DGNX NYSE
- CDNA Nasdaq
- Market Cap
- DGNX 1.2B
- CDNA 1.0B
- IPO Year
- DGNX 2025
- CDNA 2014
- Fundamental
- Price
- DGNX $45.00
- CDNA $19.04
- Analyst Decision
- DGNX
- CDNA Buy
- Analyst Count
- DGNX 0
- CDNA 6
- Target Price
- DGNX N/A
- CDNA $30.33
- AVG Volume (30 Days)
- DGNX 54.9K
- CDNA 996.2K
- Earning Date
- DGNX 01-01-0001
- CDNA 07-30-2025
- Dividend Yield
- DGNX N/A
- CDNA N/A
- EPS Growth
- DGNX N/A
- CDNA N/A
- EPS
- DGNX N/A
- CDNA 1.07
- Revenue
- DGNX $1,177,066.00
- CDNA $346,421,000.00
- Revenue This Year
- DGNX N/A
- CDNA $13.31
- Revenue Next Year
- DGNX N/A
- CDNA $15.46
- P/E Ratio
- DGNX N/A
- CDNA $17.61
- Revenue Growth
- DGNX N/A
- CDNA 25.92
- 52 Week Low
- DGNX $3.60
- CDNA $13.48
- 52 Week High
- DGNX $155.00
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- CDNA 55.64
- Support Level
- DGNX N/A
- CDNA $18.51
- Resistance Level
- DGNX N/A
- CDNA $19.62
- Average True Range (ATR)
- DGNX 0.00
- CDNA 0.84
- MACD
- DGNX 0.00
- CDNA 0.02
- Stochastic Oscillator
- DGNX 0.00
- CDNA 66.12
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.